Top Markets
Coin of the day
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Rang in Aktien #37014
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating... Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke. Additionally, it is conducting two other Phase II trials concerning significant cardiovascular emergencies, with anticipated clinical data expected from both its ischemic stroke research and studies related to COVID-19 respiratory distress syndrome. Established in 2013, the company operates from its headquarters in Paris, France.
Aktienkurs
$0.25974701
Zuletzt synchronisiert: 2025-01-06
Marktkapitalisierung
$2.04M
Veränderung (1 Tag)
0.74%
Veränderung (1 Jahr)
0.00%
Land
FR
Handel Acticor Biotech SAS (ALACT)

Kategorie

EPS für Acticor Biotech SAS (ALACT)
EPS zum June 2024 TTM: $-1.95
Laut den aktuellen Finanzberichten und dem Aktienkurs von Acticor Biotech SAS beträgt das aktuelle EPS des Unternehmens (TTM) $-1.95. Am Ende des Jahres 2022 betrug das EPS $-1.62 ein Rückgang im Vergleich zu dem EPS von 2021, das $-1.84 betrug.
EPS-Verlauf von Acticor Biotech SAS von 2010 bis 2026
EPS am Ende jedes Jahres
Jahr EPS ändert
2026 (TTM) $-1.95 -99.90%
2023 0.00 -99.90%
2022 $-1.62 -12.08%
2021 $-1.84 26.05%
2020 $-1.46 35.69%
2019 $-1.08 -51.93%
2018 $-2.24 -40.33%
2017 $-3.76 2,449.69%
2016 $-0.15 -66.91%
2015 $-0.45 26.87%
2014 $-0.35 -143.25%
2013 $0.81 -9.55%
2012 $0.90 35.87%
2011 $0.66 462.35%
2010 $0.12 0.00%
EPS für ähnliche Unternehmen oder Wettbewerber
Unternehmen EPS EPS-Differenz Land
$17.32 -986.39%
US
$27.74 -1,519.65%
NL
$-5.29 170.73%
AU
$-7.98 308.39%
US
- -
CH